Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
Axsome adds AZ asset through Avenue subsidiary acquisition
Axsome is after BAER-101, a phase 2 oral GABA receptor modulator that Avenue's Baergic Bio originally licensed from AstraZeneca in December 2019.
Darren Incorvaia
Nov 6, 2025 10:50am
UroGen hands CTLA-4 drug back to Agenus after mulling ph. 1 data
Nov 6, 2025 10:00am
Dynavax pays Vaxart $30M for oral COVID-19 vaccine program
Nov 6, 2025 5:50am
Lilly pulls out of CNS portion of $960M collab with Rigel
Nov 5, 2025 7:00am
Lilly inks $345M antibody pact with XtalPi subsidiary
Nov 5, 2025 7:00am
Prelude loses CMO, pauses SMARCA2 degraders, scores Incyte cash
Nov 4, 2025 9:40am
